Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma.
Gouda MA, Stephen B, Tian Y, Alshawa A, Onwugaje DOC, Albittar A, Yang Y, Zarifa A, Yilmaz B, Gurses S, Sprenger A, Derbala MH, Brink A, How JA, Moyers J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Patel SP, Oliva IG. Gouda MA, et al. Among authors: patel sp. J Immunother Precis Oncol. 2024 Nov 1;7(4):247-254. doi: 10.36401/JIPO-24-3. eCollection 2024 Nov. J Immunother Precis Oncol. 2024. PMID: 39524469 Free PMC article.
A phase II study of gefitinib in patients with metastatic melanoma.
Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY. Patel SP, et al. Melanoma Res. 2011 Aug;21(4):357-63. doi: 10.1097/CMR.0b013e3283471073. Melanoma Res. 2011. PMID: 21738104 Free PMC article. Clinical Trial.
BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. Janku F, et al. Among authors: patel sp. Oncotarget. 2015 Sep 29;6(29):26886-94. doi: 10.18632/oncotarget.4723. Oncotarget. 2015. PMID: 26330075 Free PMC article.
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL Jr, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Chen G, et al. Among authors: patel sp. JAMA Oncol. 2016 Aug 1;2(8):1056-64. doi: 10.1001/jamaoncol.2016.0509. JAMA Oncol. 2016. PMID: 27124486 Free PMC article. Clinical Trial.
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.
Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. Janku F, et al. Mol Cancer Ther. 2016 Jun;15(6):1397-404. doi: 10.1158/1535-7163.MCT-15-0712. Epub 2016 May 20. Mol Cancer Ther. 2016. PMID: 27207774
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.
Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF. Buchbinder EI, et al. Among authors: patel sp. J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016. J Immunother Cancer. 2016. PMID: 27660706 Free PMC article.
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Patel SP, Kim DW, Bassett RL, Cain S, Washington E, Hwu WJ, Kim KB, Papadopoulos NE, Homsi J, Hwu P, Bedikian AY. Patel SP, et al. Cancer Immunol Immunother. 2017 Oct;66(10):1359-1366. doi: 10.1007/s00262-017-2030-y. Epub 2017 Jun 13. Cancer Immunol Immunother. 2017. PMID: 28612140 Free PMC article. Clinical Trial.
Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver.
Vera-Aguilera J, Bedikian AY, Bassett RL, Hwu WJ, Kim KB, Qin Y, Cain S, Washington EW, Davies MA, Patel SM, Homsi J, Papadopoulos NE, Hwu P, Patel SP. Vera-Aguilera J, et al. Among authors: patel sp, patel sm. Am J Clin Oncol. 2018 Nov;41(11):1132-1136. doi: 10.1097/COC.0000000000000436. Am J Clin Oncol. 2018. PMID: 29509591 Free PMC article.
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Bhatty M, et al. Among authors: patel sp. Cancer. 2019 Feb 1;125(3):463-472. doi: 10.1002/cncr.31812. Epub 2018 Nov 1. Cancer. 2019. PMID: 30383888 Free PMC article. Clinical Trial.
452 results